Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Fat oxidation is impaired during exercise in lipin-1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Secular trends in risk of stroke according to body mass index and blood pressure, 1976-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. MAIT cell subtypes in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Amyloid transthyretinkardiomyopati

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cytomegalovirus-specific CD8+ T-cell responses are associated with arterial blood pressure in people living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease is often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established as reliable indicators of treatment response, despite substantial, biologically measurable effects. We studied the biologic response to treatment in a cohort of NAb-negative patients to test whether difference in responsiveness could segregate patients with and without breakthrough disease during therapy.
Original languageEnglish
JournalNeurology
Volume74
Issue number18
Pages (from-to)1455-62
Number of pages8
DOIs
Publication statusPublished - 4 May 2010

ID: 31029944